Fluocinonide

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

• Jun 10, 1987ANDAANDA071500Sun Pharma Canada
• Jan 19, 1989ANDAANDA072494Taro
• Feb 6, 1989ANDAANDA072488Teva
• Feb 7, 1989ANDAANDA072490Teva
• Dec 27, 1991ANDAANDA073481Teva
• Feb 14, 1992ANDAANDA073085Cosette
• Feb 27, 1995ANDAANDA072934Fougera Pharms Inc
• Feb 11, 2005NDANDA021758Bausch

1. 1Drug Ineffective76214%
2. 2Psoriasis5509.9%
3. 3Rash4498.0%
4. 4Pruritus4197.5%
5. 5Diarrhoea2875.1%
6. 6Fatigue2875.1%
7. 7Nausea2805.0%
8. 8Pain2775.0%
9. 9Off Label Use2704.8%
10. 10Headache2604.7%
11. 11Product Use In Unapproved Indication2153.9%
12. 12Arthralgia2113.8%
13. 13Product Dose Omission Issue1843.3%
14. 14Dermatitis Atopic1813.2%
15. 15Dyspnoea1753.1%

Recent PubMed references pinned to Fluocinonide as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial.
  Oral diseases · 2025 · Polizzi A, Tartaglia GM, Santonocito S, et al.
  PMID 39402896DOI 10.1111/odi.15156
• Central serous retinopathy associated with topical oral corticosteroid use: a case report.
  Journal of medical case reports · 2019 · O'Brien P, Young RC, Ghafoori SD, et al.
  PMID 31262360DOI 10.1186/s13256-019-2143-3
• Successful management of pediatric oral pemphigus vulgaris with topical corticosteroid monotherapy.
  Pediatric dermatology · 2019 · Le M, Ghazawi FM, Miedzybrodzki B, et al.
  PMID 31177575DOI 10.1111/pde.13876
• Tumescent Liposuction-Induced Koebnerization of Lichen Planus.
  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2019 · Tran J, Friedmann DP, Safaian C, et al.
  PMID 30608289DOI 10.1097/DSS.0000000000001752
• Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring.
  The British journal of dermatology · 2017 · Alinia H, Moradi Tuchayi S, Smith JA, et al.
  PMID 27664969DOI 10.1111/bjd.15085
• Hypoadrenalism secondary to topical corticosteroid-containing skin-lightening cream: danger of over-the-counter cosmetic agents.
  The Medical journal of Australia · 2015 · Lee AS, Perera NJ, Chua EL, et al.
  PMID 26424061DOI 10.5694/mja15.00413
• Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study.
  Cutis · 2015 · Draelos ZD
  PMID 26367752
• Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis.
  Dermatology online journal · 2013 · Hix E, Gustafson CJ, O'Neill JL, et al.
  PMID 24139369

The 10 most recently updated of 14 ClinicalTrials.gov registrations naming Fluocinonide as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
  Recruiting · Phase 1 · Interventional · 86 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT06504160updated 2026-06-02
• Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
  Recruiting · Phase 4 · Interventional · 250 enrolled · Wake Forest University Health Sciences
  NCT04207931updated 2026-03-31
• Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.
  Recruiting · Phase 4 · Interventional · 104 enrolled · Instituto Mexicano del Seguro Social
  NCT07073846updated 2025-11-28
• Cutaneous Lupus Medication Experience Study
  Completed · Observational · 11 enrolled · Wake Forest University Health Sciences
  NCT02176148updated 2025-04-24
• Impact of Fluocinonide 0,05% in Oral Lichen Planus
  Completed · Interventional · 47 enrolled · University of Catania
  NCT06135805updated 2024-09-19
• Improvement of Psoriasis Patients' Adherence to Topical Drugs
  Completed · Interventional · 103 enrolled · Odense University Hospital
  NCT04220554updated 2024-01-30
• Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
  Withdrawn · Interventional · 0 enrolled · Rochester General Hospital
  NCT02301494updated 2021-04-27
• Using an Internet Study to Improve Adherence for Psoriasis Patients
  Completed · Early phase 1 · Interventional · 40 enrolled · Wake Forest University
  NCT01802580updated 2020-06-04
• Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
  Completed · Interventional · 24 enrolled · University of Texas Southwestern Medical Center
  NCT00812188updated 2019-02-18
• Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
  Completed · Phase 2 · Interventional · 10 enrolled · Wake Forest University
  NCT01469767updated 2018-09-07

Frequently asked questions

How does Fluocinonide work?

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

What class of drug is Fluocinonide?

Fluocinonide is classified as Corticosteroids, Corticosteroids, potent (group III), Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Lipoxygenase Inhibitors, Antipruritic Activity, Decreased Immunologically Active Molecule Activity, Decreased Protein Synthesis, Vasoconstriction.

What are the brand names for Fluocinonide?

Fluocinonide is marketed under brand names including Vanos.